PepGen Inc. (PEPG)

NASDAQ: PEPG · IEX Real-Time Price · USD
15.69
+0.07 (0.45%)
Feb 1, 2023, 4:00 PM EST - Market closed
0.45%
Market Cap 370.78M
Revenue (ttm) n/a
Net Income (ttm) -61.31M
Shares Out 23.63M
EPS (ttm) -42.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,989
Open 15.62
Previous Close 15.62
Day's Range 15.32 - 15.90
52-Week Range 4.32 - 17.81
Beta n/a
Analysts Buy
Price Target 24.89 (+58.64%)
Earnings Date Feb 9, 2023

About PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2022
Employees 40
Stock Exchange NASDAQ
Ticker Symbol PEPG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $24.89, which is an increase of 58.64% from the latest price.

Price Target
$24.89
(58.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going

PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through o...

1 day ago - Zacks Investment Research

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

- PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically relevant doses-

2 months ago - GlobeNewsWire

Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High?

The consensus price target hints at a 50.4% upside potential for PepGen, Inc. (PEPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

2 months ago - Zacks Investment Research

What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing'

PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through o...

2 months ago - Zacks Investment Research

Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 68.1% in PepGen, Inc. (PEPG). While the effectiveness of this highly sought-after metric is questionable, the p...

2 months ago - Zacks Investment Research

PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

- In non-human primates (NHPs), high levels of exon 53 skipping were observed after a single dose of PGN-EDO53 – almost 7-times higher than those observed for a comparator peptide-phosphorodiamidate m...

2 months ago - GlobeNewsWire

PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

3 months ago - GlobeNewsWire

PepGen to Participate in the Stifel 2022 Healthcare Conference

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

3 months ago - GlobeNewsWire

PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming th...

3 months ago - GlobeNewsWire

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 s...

4 months ago - GlobeNewsWire

PepGen Appoints Habib Dable to Board of Directors

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the t...

4 months ago - GlobeNewsWire

3 IPO stocks to watch in September: PEPG, PFHC, HNVR

Initial public offerings (IPOs) are often the most common route companies use to hit the public markets and raise money

Other symbols: HNVR
5 months ago - Finbold

PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the tr...

6 months ago - GlobeNewsWire

PepGen Appoints Caroline Godfrey, Ph.D. to the Company's Scientific Advisory Board

BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transf...

6 months ago - GlobeNewsWire

Biotech Public Offerings at 10-Year Low

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerin...

Other symbols: BLTEHLVXTAKXBI
7 months ago - GuruFocus

PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the tr...

8 months ago - GlobeNewsWire

It's Time To Nibble On These Two Recent IPOs

It's hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen (...

Other symbols: BLCO
8 months ago - MarketBeat

Andreas Halvorsen's Firm Packs Into PepGen and Mastercard

Andreas Halvorsen (Trades, Portfolio), founding partner and chief investment officer of Viking Global Investors LP, disclosed in a regulatory SEC 13G filing that his firm entered positions in PepGen I...

Other symbols: MA
9 months ago - GuruFocus

PepGen Announces Pricing of Initial Public Offering

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...

9 months ago - GlobeNewsWire